During favorable market conditions, the fund appreciates along the lines of the underlying index. All Rights Reserved. Its investment capacity currently exceeds €1 billion and rises to twice this amount when including its strategic investment partners. Amet null vulputate tristique urna, nec feugiat lorem ipsum dolor vitae ante vitae mauris sed turpis aliquam eleifend id pulvinar aliquam eleifend id pulvinar metus sed lorem.
The remaining 90% are left in cash and invested in fixed income securities. Investment size from EUR 5M to 300M. The offer, sale or delivery of the securities within the United States or to, or for the account or benefit of, U.S. The oversubscribed fund closed above the global private equity healthcare specialist’s €800 million target, notwithstanding the impact of the Covid-19 pandemic. ArchiMed’s €1 billion ($1.2 billion) mid-market buy-and-build fund, MED Platform I, attracted major commitments from a broad range of institutional investors and family offices in both Europe (70 percent) and North America (30 percent).… In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions. Instead of investing directly into equities, the fund uses approximately 10% of its asse ts to replicate a 100% stock weighted portfolio by way of using derivatives on selected indices. ArchiMed is an independent Lyon-based investment firm founded in 2014 and acts as a strategic financial partner for European healthcare companies.
The Archimedes Invest Plus fund possesses the character of an equity fund used as core investment with a longer-term investment horizon. Archimed's maiden fund will focus exclusively on the European healthcare space, targeting subsectors such as medtech, biopharma and healthcare providers. Instead of investing directly into equities, the fund uses approximately 10% of its assets to replicate a 100% stock weighted portfolio by way of using derivatives on selected indices.
In May 2019, ArchiMed completed its first investment in Bomi, an Italian healthcare logistics company focusing on the medical devices, biomedical and in vitro diagnostics sectors. ArchiMed has over €1.7 billion (over $2 billion) under management. Investor Portal | Copyright © 2020 ArchiMed | contact@archimed-group.eu | Legal Notice | Design Agence Sand, An independent investment firm specialized in the Healthcare industries. As an index tracker - but unlike index based ETFs – Archimedes offers a limited annual (calendar year) capital protection with the potential loss on the derivative position being restricted to the 10%. “As with our other funds, MED Platform I empowers talented management teams to take their companies to the major leagues.”, “ArchiMed has the expertise and the financial power to help both small and mid-sized companies scale up at speed,” adds André-Michel Ballester, Managing Partner of the MED Platform I fund.